Brian Alexander joins Champions Oncology (NASDAQ: CSBR) board
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Champions Oncology, Inc. reported that its Board of Directors accepted the resignation of Dr. Philip Breitfeld and appointed Dr. Brian Alexander as a director to fill the vacancy. The company stated that Dr. Breitfeld’s resignation was not due to any disagreement over operations, policies, or practices.
The company noted there is no arrangement or understanding with other persons regarding Dr. Alexander’s appointment, no related-party transactions requiring disclosure, and no material plans or contracts tied to his appointment. Dr. Alexander is an experienced oncology and data-science leader, currently serving as CEO of Valo Health and CEO-Partner at Flagship Pioneering.
Champions Oncology highlighted that his background in oncology, artificial intelligence, and data-driven drug development supports its strategy of linking patient-derived tumor models with molecular and clinical datasets to power a more data-informed translational research platform.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Terms
translational oncology research, patient-derived xenograft (PDX), multi-omic, data platform and analytics, +1 more
5 terms
translational oncology research financial
"a leading translational oncology research organization"
patient-derived xenograft (PDX) financial
"largest and most annotated bank of clinically relevant patient-derived xenograft (PDX)"
multi-omic financial
"link tumor models with multi-omic and patient data"
Multi-omic describes the combined analysis of different biological data types—such as genes, proteins and small molecules—to get a fuller picture of how living systems work. Think of it like studying a recipe (genes), the ingredients list (proteins) and the final dish (metabolites) together rather than separately. For investors, multi-omic approaches can improve drug discovery, diagnostics and patient targeting, potentially raising the odds of successful, marketable products.
data platform and analytics financial
"groundbreaking data platform and analytics, and scientific excellence"
oncology R&D continuum financial
"support partners across the oncology R&D continuum, from early discovery"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 24, 2026
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||||||||||||
| of Incorporation) | Identification No.) | |||||||||||||
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201 ) 808-8400
N/A
(Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Securities registered pursuant to Section 12(b) of the Exchange Act
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||||||||
| Common Stock, par value $0.001 per share | CSBR | The Nasdaq Stock Market LLC | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | |||||||
On March 24, 2026, the Board of Directors (the “Board”) of Champions Oncology, Inc. (the “Company”) accepted the resignation of Dr. Philip Breitfeld as a member of the Board and appointed Dr. Brian Alexander as a director of the Company to fill the vacancy created by Dr. Breitfeld’s resignation. Dr. Breitfeld’s decision to resign was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
There is no arrangement or understanding between Dr. Alexander and any other persons pursuant to Dr. Alexander’s appointment as a director and there are no related party transactions involving Dr. Alexander that are reportable under Item 404(a) of Regulation S-K. There are no material plans, contracts or arrangements to which Dr. Alexander is a party to or in which he participates, nor have there been any material amendment to any plan, contract or arrangement by virtue of Dr. Alexander’s appointment.
The following is certain biographical information regarding Dr. Alexander:
Dr. Alexander, MD, MPH, serves as the Chief Executive Officer of Valo Health Inc., a company dedicated to utilizing artificial intelligence (AI) and advanced analytics to learn from patient experiences and accelerate the discovery and development of superior medicines at increased speed and scale, since November 2024. Additionally, he holds the position of CEO-Partner at Flagship Pioneering since November 2024. Prior to joining Valo Health and Flagship Pioneering, Dr. Alexander worked as the Senior Vice President for Research & Development at Roche/Genentech, from November 2023 to November 2024, working to leverage data sciences and AI/ML approaches for innovative clinical developmental strategies. From 2018 to November 2023, Dr. Alexander held various positions at Foundation Medicine, including the role of Chief Executive Officer beginning in April 2021. Dr. Alexander serves on the Board of Directors of MassBio, a bio-tech firm, and is a co‑founder and board member of the Global Coalition for Adaptive Research, a nonprofit organization focused on accelerating the discovery and development of treatments for patients with rare and deadly diseases through pioneering, patient‑centric clinical trial design. He was also the founding director of the Harvard/MIT Center for Regulatory Science.
Dr. Alexander previously served as an Associate Professor at Harvard Medical School and as a radiation oncologist at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. He received his MD from the University of Michigan, MPH from the Harvard School of Public Health, and served as a White House Fellow in the George W. Bush and Barack Obama administrations.
| Item 9.01. | Financial Statements and Exhibits. | |||||||
(d)Exhibits
The following exhibit is filed herewith:
Exhibit No.
| 99.1 | Press Release dated March 30, 2026 | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CHAMPIONS ONCOLOGY, INC. | |||||||||||
| (Registrant) | |||||||||||
| Date: March 30, 2026 | By: | /s/ Robert Brainin | |||||||||
| Robert Brainin | |||||||||||
| Chief Executive Officer | |||||||||||
Exhibit 99.1
NEWSOne University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D
Hackensack, NJ – March 30, 2026 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine. His addition supports Champions' strategy to expand the use of clinically relevant data to inform drug discovery and development.
Champions is advancing an approach that connects its portfolio of patient-derived tumor models with molecular and clinical datasets to drive more informed decision-making across the drug development lifecycle. This foundation enables the use of advanced analytics and AI to generate deeper insights into disease biology and improve R&D outcomes. Dr. Alexander's appointment reflects the Company's continued investment in this capability and its evolution toward a more connected translational research platform.
"Brian brings a unique combination of clinical, scientific, and data-driven leadership experience that aligns closely with where Champions is heading," said Ronnie Morris, Chairman of the Board at Champions Oncology. "As we continue to expand our data capabilities, his perspective will help us better link tumor models with multi-omic and patient data, accelerate discovery, and support more efficient clinical development."
Exhibit 99.1
"I'm excited to join Champions at an important point in its evolution," said Dr. Alexander. "The ability to connect well characterized tumor models with rich datasets creates a powerful opportunity to deepen our understanding of disease and enable more informed therapeutic development. I look forward to working with the team to advance this approach."
Champions Oncology is building an integrated platform centered on PDX models, combining patient-derived tumors with comprehensive molecular and clinical data. This approach enhances its ability to support partners across the oncology R&D continuum, from early discovery through translational development, with a more data-informed and analytically driven strategy.
To learn more about how Champions Data Services powers oncology drug discovery, visit: https://www.championsoncology.com/data-ecosystem
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative, highest-quality data through proprietary in vivo and ex vivo platforms. Utilizing its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
+1 (518) 488 9062
FAQ
What board change did Champions Oncology (CSBR) disclose in this 8-K?
Champions Oncology disclosed that Dr. Philip Breitfeld resigned from its Board of Directors and was replaced by Dr. Brian Alexander. The company stated Breitfeld’s resignation was not due to any disagreement regarding operations, policies, or practices at Champions Oncology.
Who is Brian Alexander and what is his role at Champions Oncology (CSBR)?
Brian Alexander, MD, MPH, has been appointed to the Champions Oncology Board of Directors. He is CEO of Valo Health and a CEO-Partner at Flagship Pioneering, with prior senior roles at Roche/Genentech and Foundation Medicine, focused on oncology, data science, and drug development.
Did Champions Oncology (CSBR) report any disagreement tied to Dr. Breitfeld’s resignation?
Champions Oncology stated that Dr. Philip Breitfeld’s decision to resign from the Board was not due to any disagreement with the company regarding its operations, policies, or practices. This language signals a routine transition rather than a dispute-driven departure from the board.
How does Brian Alexander’s background align with Champions Oncology’s strategy?
Brian Alexander has extensive experience integrating oncology, data science, and AI from roles at Valo Health, Flagship Pioneering, Roche/Genentech, and Foundation Medicine. Champions Oncology highlighted this background as supporting its data-driven strategy linking tumor models with molecular and clinical datasets for oncology R&D.
What strategic focus did Champions Oncology emphasize in announcing this board change?
Champions Oncology emphasized a strategy centered on connecting its patient-derived tumor models with molecular and clinical data to support data-driven oncology R&D. The company said Dr. Alexander’s expertise in AI and advanced analytics aligns with its evolving translational research and data platform approach.
Filing Exhibits & Attachments
4 documents
Champions Oncolo
NASDAQ:CSBR
CSBR Rankings
CSBR Latest News
CSBR Latest SEC Filings
CSBR Stock Data
80.40M
10.18M
Biotechnology
Biological Products, (no Diagnostic Substances)
United States
BALTIMORE